

# Pain Therapeutics Conference - Reviewing current opportunities in the effective and safe management of pain

*SMI's 15th annual Pain Therapeutics conference will be taking place on the 18th - 19th May 2015 in London, UK. Book by 27th February to save £300*

LONDON, ENGLAND, UNITED KINGDOM, February 27, 2015

[/EINPresswire.com/](http://EINPresswire.com/) -- We are delighted to announce that Mark T Brown, MD, Executive Director, Tanezumab Clinical Program Leader for Osteoarthritis and Cancer Pain Studies, from Pfizer has joined our expert panel on day two, his presentation is entitled: Update on Tanezumab, a monoclonal antibody inhibitor of nerve growth factor, looking at the following areas: rationale for NGF inhibition in treatment of chronic pain, review of tanezumab efficacy in completed chronic pain studies and update on current status of tanezumab development

A promotional poster for the SMI 15th annual Pain Therapeutics Conference. The poster features the SMI logo (a stylized arrow pointing right) and the tagline 'LINKING BUSINESS with INFORMATION'. The main title 'Pain Therapeutics Conference' is in a large, purple, serif font. Below the title, it says 'Holiday Inn Bloomsbury, London, UK' and '18th - 19th MAY 2015'. On the left side, there is a graphic of a human torso showing the skeletal structure and muscles, with a yellow and red glow around the shoulder joint, indicating pain. At the bottom, the website 'www.pain-therapeutics.co.uk' is displayed in white text on a black background.

SMI's [Pain Therapeutics conference](#) is a must attend event for attendees who want to benchmark their organisation with recent developments in the pain therapeutics arena and methods on how to overcome the challenges faced. The [conference](#) will examine principles and illustrative case studies on current activities and trends in clinical and pre-clinical evidence-based and best-practice-based pain medicine.

Benefits of Attending Include:

- New for 2015 - Presentations on personalized medicine for pain, biomarkers and CGRP receptor antagonists for migraine treatment
- Learn about Grunenthal's latest screening approach for neuropathic pain and pain models

- Hear timely case studies from Merck and Afferent Pharmaceuticals
- Spotlight sessions - Latest updates on developments in targeting nerve growth factors
- Discover latest advances in the treatment of pain from leading, pharma, biotech and academic experts from the industry
- Interactive panel discussion the reviewing validity of animal models for chronic pain

Pain Therapeutics is sponsored by: CHDR & PRA Health Sciences

[Click here](#) for more information or to register.

Alternatively, contact Magdalena Georgieva on +44 (0)20 7827 6148 or email [mgeorgieva@smi-online.co.uk](mailto:mgeorgieva@smi-online.co.uk)

----- END -----

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

sam mahoney  
SMi Group Ltd  
+442078276000  
[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/252195206>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.